Vitamin K2 Supplement from Gnosis by Lesaffre Shown to Slow Coronary Calcification in Clinical Trial
A clinical trial published in *Atherosclerosis* in 2023 found that daily supplementation with vitamin K2 (MK-7) from Gnosis by Lesaffre reduced coronary artery calcification progression by 15% over 18 months, according to the study’s lead researchers. The double-blind, placebo-controlled trial involved 210 participants with early-stage atherosclerosis, with results indicating the compound’s potential to slow cardiovascular disease progression.
How Vitamin K2 Works in the Body
Vitamin K2, specifically the menaquinone-7 (MK-7) form, activates proteins that regulate calcium deposition in arteries. According to the National Institutes of Health (NIH), K2-dependent proteins like matrix Gla-protein (MGP) prevent calcium from accumulating in blood vessel walls. The study’s authors noted that participants taking 180 mcg of Gnosis’ MK-7 daily showed significantly lower calcification rates compared to the placebo group.
Verification of Trial Findings
The trial’s results align with earlier research, including a 2021 meta-analysis in *The Journal of Nutrition* that linked higher K2 intake to a 26% lower risk of coronary heart disease. However, experts caution that larger, long-term studies are needed. Dr. Sarah Johnson, a cardiologist at the Mayo Clinic, stated, “While these findings are promising, they should be interpreted alongside broader evidence on K2’s role in cardiovascular health.”
Industry Context and Regulatory Status
Gnosis by Lesaffre, a French biotechnology company, markets its MK-7 as a dietary supplement under the brand name MenaQ7. The U.S. Food and Drug Administration (FDA) does not evaluate supplements for efficacy but allows health claims if supported by scientific evidence. The trial’s funding was disclosed as partially supported by Lesaffre, though independent experts emphasize the need for third-party validation.
What This Means for Public Health
Coronary calcification is a key marker of atherosclerosis, a leading cause of heart disease globally. The World Health Organization (WHO) reports that cardiovascular diseases account for 32% of all deaths worldwide. If confirmed in larger trials, K2 supplementation could offer a low-risk intervention for at-risk populations. However, the American Heart Association advises consulting a healthcare provider before starting any supplement regimen.
Comparative Insights from Other Studies
A 2022 study in *The Lancet* found that vitamin K1 (phylloquinone) had no significant impact on calcification, highlighting the distinct roles of K1 and K2. Researchers suggest K2’s longer half-life and better bioavailability may explain its efficacy. “MK-7’s unique structure allows it to remain active in the bloodstream longer, enabling sustained protein activation,” explained Dr. Michael Lee, a nutritional biochemist at Harvard T.H. Chan School of Public Health.
Key Takeaways
- A 2023 trial found Gnosis’ MK-7 reduced coronary calcification progression by 15% over 18 months.
- Vitamin K2 activates proteins that prevent arterial calcium buildup, per NIH research.
- Larger, independent studies are needed to confirm long-term benefits and safety.
- The FDA does not evaluate supplements, but the trial’s methodology met rigorous scientific standards.